0 XP   0   0   0

Mithra Pharmaceuticals SA
Buy, Hold or Sell?

Should you buy, hold or sell Mithra?

I guess you are interested in Mithra Pharmaceuticals SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Mithra

Let's start. I'm going to help you getting a better view of Mithra Pharmaceuticals SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Mithra Pharmaceuticals SA even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Mithra Pharmaceuticals SA is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Mithra Pharmaceuticals SA. The closing price on 2023-01-27 was €3.35 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Mithra Pharmaceuticals SA Daily Candlestick Chart
Mithra Pharmaceuticals SA Daily Candlestick Chart
Summary









1. Valuation of Mithra




Current price per share

€3.35

2. Growth of Mithra




Is Mithra growing?

Current yearPrevious yearGrowGrow %
How rich?$36.7m$171.4m-$134.6m-366.1%

How much money is Mithra making?

Current yearPrevious yearGrowGrow %
Making money-$127m-$100m-$26.9m-21.2%
Net Profit Margin-515.6%-1,019.8%--

How much money comes from the company's main activities?

3. Financial Health of Mithra




Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry




  Industry Rankings (Drug Manufacturers-Specialty & Generic)  


Richest
#504 / 705

Most Revenue
#478 / 705

Most Profit
#656 / 705

Most Efficient
#636 / 705


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

1.1. Profitability of Mithra Pharmaceuticals SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mithra earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Mithra to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of -515.6% means that €-5.16 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mithra Pharmaceuticals SA:

  • The MRQ is -515.6%. The company is making a huge loss. -2
  • The TTM is -515.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-515.6%TTM-515.6%0.0%
TTM-515.6%YOY-1,019.8%+504.2%
TTM-515.6%5Y-332.0%-183.6%
5Y-332.0%10Y-193.7%-138.3%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-515.6%0.4%-516.0%
TTM-515.6%0.3%-515.9%
YOY-1,019.8%0.2%-1,020.0%
5Y-332.0%-0.7%-331.3%
10Y-193.7%-0.1%-193.6%
1.1.2. Return on Assets

Shows how efficient Mithra is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mithra to the Drug Manufacturers-Specialty & Generic industry mean.
  • -27.7% Return on Assets means that Mithra generated €-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mithra Pharmaceuticals SA:

  • The MRQ is -27.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.7%TTM-27.7%0.0%
TTM-27.7%YOY-17.6%-10.1%
TTM-27.7%5Y-14.0%-13.7%
5Y-14.0%10Y-13.3%-0.7%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.7%0.1%-27.8%
TTM-27.7%0.1%-27.8%
YOY-17.6%-0.1%-17.5%
5Y-14.0%-0.2%-13.8%
10Y-13.3%0.1%-13.4%
1.1.3. Return on Equity

Shows how efficient Mithra is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mithra to the Drug Manufacturers-Specialty & Generic industry mean.
  • -345.4% Return on Equity means Mithra generated €-3.45 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mithra Pharmaceuticals SA:

  • The MRQ is -345.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -345.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-345.4%TTM-345.4%0.0%
TTM-345.4%YOY-58.4%-287.0%
TTM-345.4%5Y-93.7%-251.7%
5Y-93.7%10Y-81.3%-12.4%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-345.4%0.6%-346.0%
TTM-345.4%0.4%-345.8%
YOY-58.4%0.4%-58.8%
5Y-93.7%-0.3%-93.4%
10Y-81.3%0.1%-81.4%

1.2. Operating Efficiency of Mithra Pharmaceuticals SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mithra is operating .

  • Measures how much profit Mithra makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mithra to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of -494.1% means the company generated €-4.94  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mithra Pharmaceuticals SA:

  • The MRQ is -494.1%. The company is operating very inefficient. -2
  • The TTM is -494.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-494.1%TTM-494.1%0.0%
TTM-494.1%YOY-1,189.6%+695.5%
TTM-494.1%5Y-368.4%-125.7%
5Y-368.4%10Y-214.9%-153.6%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-494.1%2.5%-496.6%
TTM-494.1%1.6%-495.7%
YOY-1,189.6%2.7%-1,192.3%
5Y-368.4%1.8%-370.2%
10Y-214.9%0.8%-215.7%
1.2.2. Operating Ratio

Measures how efficient Mithra is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 4.88 means that the operating costs are €4.88 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 4.877. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.877. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.877TTM4.8770.000
TTM4.877YOY10.267-5.390
TTM4.8775Y3.618+1.259
5Y3.61810Y2.589+1.029
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8771.473+3.404
TTM4.8771.456+3.421
YOY10.2671.398+8.869
5Y3.6181.374+2.244
10Y2.5891.191+1.398

1.3. Liquidity of Mithra Pharmaceuticals SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mithra is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 1.04 means the company has €1.04 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 1.038. The company is just able to pay all its short-term debts.
  • The TTM is 1.038. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.038TTM1.0380.000
TTM1.038YOY3.371-2.333
TTM1.0385Y2.401-1.363
5Y2.40110Y1.953+0.447
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0381.880-0.842
TTM1.0381.901-0.863
YOY3.3712.112+1.259
5Y2.4012.182+0.219
10Y1.9531.891+0.062
1.3.2. Quick Ratio

Measures if Mithra is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mithra to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 0.54 means the company can pay off €0.54 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.540. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.540. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.540TTM0.5400.000
TTM0.540YOY2.797-2.257
TTM0.5405Y1.941-1.402
5Y1.94110Y2.022-0.081
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5400.733-0.193
TTM0.5400.796-0.256
YOY2.7970.808+1.989
5Y1.9410.834+1.107
10Y2.0220.821+1.201

1.4. Solvency of Mithra Pharmaceuticals SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mithra assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mithra to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.92 means that Mithra assets are financed with 92.0% credit (debt) and the remaining percentage (100% - 92.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 0.920. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.920. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.920TTM0.9200.000
TTM0.920YOY0.698+0.222
TTM0.9205Y0.686+0.234
5Y0.68610Y0.676+0.009
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9200.437+0.483
TTM0.9200.424+0.496
YOY0.6980.398+0.300
5Y0.6860.398+0.288
10Y0.6760.401+0.275
1.4.2. Debt to Equity Ratio

Measures if Mithra is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mithra to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 1,146.8% means that company has €11.47 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is 11.468. The company is unable to pay all its debts with equity. -1
  • The TTM is 11.468. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ11.468TTM11.4680.000
TTM11.468YOY2.309+9.159
TTM11.4685Y3.677+7.791
5Y3.67710Y3.750-0.073
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ11.4680.652+10.816
TTM11.4680.675+10.793
YOY2.3090.623+1.686
5Y3.6770.684+2.993
10Y3.7500.697+3.053

2. Market Valuation of Mithra Pharmaceuticals SA

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Mithra generates.

  • Above 15 is considered overpriced but always compare Mithra to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of -18.37 means the investor is paying €-18.37 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is -3.081. Company is losing money. -2
  • The MRQ is -18.375. Company is losing money. -2
  • The TTM is -18.375. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-3.081MRQ-18.375+15.294
MRQ-18.375TTM-18.3750.000
TTM-18.375YOY-11.845-6.530
TTM-18.3755Y-38.151+19.776
5Y-38.15110Y-26.250-11.901
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD-3.081-0.124-2.957
MRQ-18.375-0.437-17.938
TTM-18.375-0.102-18.273
YOY-11.84515.340-27.185
5Y-38.1517.916-46.067
10Y-26.2507.700-33.950
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Mithra.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Mithra Pharmaceuticals SA:

  • The MRQ is -13.649. Very Bad. -2
  • The TTM is -13.649. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-13.649TTM-13.6490.000
TTM-13.649YOY8.077-21.726
TTM-13.6495Y58.403-72.052
5Y58.40310Y49.216+9.187
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.6490.012-13.661
TTM-13.6490.010-13.659
YOY8.0770.004+8.073
5Y58.4030.010+58.393
10Y49.2160.021+49.195

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mithra is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 63.46 means the investor is paying €63.46 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Mithra Pharmaceuticals SA:

  • The EOD is 10.641. Seems overpriced? -1
  • The MRQ is 63.462. Seems overpriced? -1
  • The TTM is 63.462. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD10.641MRQ63.462-52.822
MRQ63.462TTM63.4620.000
TTM63.462YOY6.915+56.547
TTM63.4625Y18.632+44.831
5Y18.63210Y10.297+8.335
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD10.6411.415+9.226
MRQ63.4621.586+61.876
TTM63.4622.019+61.443
YOY6.9152.230+4.685
5Y18.6321.895+16.737
10Y10.2971.505+8.792
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Mithra Pharmaceuticals SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.534-2.5340%-0.100-96%-0.273-89%0.031-8149%
Book Value Growth--0.2150.2150%0.966-78%0.987-78%3.576-94%
Book Value Per Share--0.3150.3150%2.849-89%2.081-85%1.457-78%
Book Value Per Share Growth--0.1110.1110%0.966-89%0.966-89%3.565-97%
Current Ratio--1.0381.0380%3.371-69%2.401-57%1.953-47%
Debt To Asset Ratio--0.9200.9200%0.698+32%0.686+34%0.676+36%
Debt To Equity Ratio--11.46811.4680%2.309+397%3.677+212%3.750+206%
Dividend Per Share----0%-0%-0%0.005-100%
Eps---1.087-1.0870%-1.663+53%-0.817-25%-0.499-54%
Eps Growth--1.3461.3460%-1.467+209%0.476+183%-0.074+105%
Free Cash Flow Per Share---0.889-0.8890%-1.738+96%-0.944+6%-0.604-32%
Free Cash Flow Per Share Growth--1.4891.4890%0.455+228%-0.570+138%-2.027+236%
Free Cash Flow To Equity Per Share---0.673-0.6730%1.606-142%0.161-517%0.230-392%
Free Cash Flow To Equity Per Share Growth---0.419-0.4190%3.385-112%2.514-117%4.209-110%
Gross Profit Margin--1.0161.0160%1.016+0%1.077-6%2.042-50%
Intrinsic Value_10Y_max---7.184--------
Intrinsic Value_10Y_min---6.214--------
Intrinsic Value_1Y_max---0.855--------
Intrinsic Value_1Y_min---0.830--------
Intrinsic Value_3Y_max---2.465--------
Intrinsic Value_3Y_min---2.330--------
Intrinsic Value_5Y_max---3.952--------
Intrinsic Value_5Y_min---3.637--------
Net Profit Margin---5.156-5.1560%-10.198+98%-3.320-36%-1.937-62%
Operating Margin---4.941-4.9410%-11.896+141%-3.684-25%-2.149-57%
Operating Ratio--4.8774.8770%10.267-53%3.618+35%2.589+88%
Pb Ratio10.641-496%63.46263.4620%6.915+818%18.632+241%10.297+516%
Pe Ratio-3.081+83%-18.375-18.3750%-11.845-36%-38.151+108%-26.250+43%
Peg Ratio---13.649-13.6490%8.077-269%58.403-123%49.216-128%
Price Per Share3.350-496%19.98019.9800%19.700+1%19.240+4%11.544+73%
Price To Total Gains Ratio-1.322+83%-7.885-7.8850%-196.110+2387%-32.423+311%-24.577+212%
Profit Growth--0.7310.7310%-1.467+301%0.353+107%-0.506+169%
Quick Ratio--0.5400.5400%2.797-81%1.941-72%2.022-73%
Return On Assets---0.277-0.2770%-0.176-36%-0.140-50%-0.133-52%
Return On Equity---3.454-3.4540%-0.584-83%-0.937-73%-0.813-76%
Revenue Growth--2.5102.5100%0.094+2583%1.516+66%1.337+88%
Total Gains Per Share---2.534-2.5340%-0.100-96%-0.273-89%0.036-7050%
Total Gains Per Share Growth---23.225-23.2250%-0.448-98%-1.844-92%2.148-1181%
Usd Book Value--36780696.00036780696.0000%171443258.400-79%128830039.620-71%89460021.750-59%
Usd Book Value Change Per Share---2.754-2.7540%-0.109-96%-0.297-89%0.034-8149%
Usd Book Value Per Share--0.3420.3420%3.096-89%2.262-85%1.584-78%
Usd Dividend Per Share----0%-0%-0%0.005-100%
Usd Eps---1.182-1.1820%-1.808+53%-0.888-25%-0.542-54%
Usd Free Cash Flow---103873946.100-103873946.1000%-104619559.500+1%-66905433.780-36%-41379369.900-60%
Usd Free Cash Flow Per Share---0.966-0.9660%-1.890+96%-1.026+6%-0.656-32%
Usd Free Cash Flow To Equity Per Share---0.731-0.7310%1.746-142%0.175-517%0.250-392%
Usd Price Per Share3.641-496%21.71621.7160%21.412+1%20.912+4%12.547+73%
Usd Profit---127031437.500-127031437.5000%-100088273.400-21%-61495497.720-52%-37099918.530-71%
Usd Revenue--24637849.20024637849.2000%9814707.000+151%50507373.480-51%35510762.040-31%
Usd Total Gains Per Share---2.754-2.7540%-0.109-96%-0.297-89%0.040-7050%
 EOD+3 -2MRQTTM+0 -0YOY+18 -225Y+9 -3110Y+7 -35

3.2. Fundamental Score

Let's check the fundamental score of Mithra Pharmaceuticals SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.081
Price to Book Ratio (EOD)Between0-110.641
Net Profit Margin (MRQ)Greater than0-5.156
Operating Margin (MRQ)Greater than0-4.941
Quick Ratio (MRQ)Greater than10.540
Current Ratio (MRQ)Greater than11.038
Debt to Asset Ratio (MRQ)Less than10.920
Debt to Equity Ratio (MRQ)Less than111.468
Return on Equity (MRQ)Greater than0.15-3.454
Return on Assets (MRQ)Greater than0.05-0.277
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Mithra Pharmaceuticals SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.050
Ma 20Greater thanMa 503.450
Ma 50Greater thanMa 1003.924
Ma 100Greater thanMa 2005.175
OpenGreater thanClose3.305
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2017-12-312018-12-312019-12-312020-12-312021-12-31
Net Tangible Assets  2,83964,01966,85811,15878,016-2,48175,535-131,965-56,430
Long-term Liabilities Other  7,7852,46610,2512,83413,085-13,0841-2-1



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets421,918
Total Liabilities388,078
Total Stockholder Equity33,840
 As reported
Total Liabilities 388,078
Total Stockholder Equity+ 33,840
Total Assets = 421,918

Assets

Total Assets421,918
Total Current Assets99,389
Long-term Assets99,389
Total Current Assets
Cash And Cash Equivalents 32,872
Net Receivables 18,844
Inventory 43,852
Total Current Assets  (as reported)99,389
Total Current Assets  (calculated)95,568
+/- 3,821
Long-term Assets
Property Plant Equipment 107,677
Goodwill 5,233
Intangible Assets 104,954
Long-term Assets Other 41,208
Long-term Assets  (as reported)322,528
Long-term Assets  (calculated)259,072
+/- 63,456

Liabilities & Shareholders' Equity

Total Current Liabilities95,793
Long-term Liabilities292,285
Total Stockholder Equity33,840
Total Current Liabilities
Short-term Debt 53,128
Short Long Term Debt 46,567
Accounts payable 16,915
Other Current Liabilities 25,750
Total Current Liabilities  (as reported)95,793
Total Current Liabilities  (calculated)142,360
+/- 46,567
Long-term Liabilities
Long term Debt 125,237
Capital Lease Obligations 48,914
Other Liabilities 9,251
Long-term Liabilities Other -1
Deferred Long Term Liability 19,917
Long-term Liabilities  (as reported)292,285
Long-term Liabilities  (calculated)203,318
+/- 88,967
Total Stockholder Equity
Common Stock32,250
Retained Earnings -336,633
Other Stockholders Equity 338,223
Total Stockholder Equity (as reported)33,840
Total Stockholder Equity (calculated)33,840
+/-0
Other
Capital Stock32,250
Cash and Short Term Investments 32,872
Common Stock Shares Outstanding 107,486
Liabilities and Stockholders Equity 421,918
Net Debt 187,846
Net Invested Capital 205,644
Net Tangible Assets -56,430
Net Working Capital 3,596
Short Long Term Debt Total 220,718



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
1,551
2,716
3,050
3,676
5,814
7,451
7,249
13,984
13,543
9,648
11,904
61,019
205,587
172,696
244,712
355,684
397,643
521,984
421,918
421,918521,984397,643355,684244,712172,696205,58761,01911,9049,64813,54313,9847,2497,4515,8143,6763,0502,7161,551
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
6,272
8,103
8,682
109,089
57,876
74,212
153,667
91,522
238,475
99,389
99,389238,47591,522153,66774,21257,876109,0898,6828,1036,272000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
703
1,561
2,113
7,794
2,150
36,190
118,949
49,720
138,675
32,872
32,872138,67549,720118,94936,1902,1507,7942,1131,561703000000000
       Short-term Investments 
598
784
262
974
505
636
1,013
460
158
0
0
0
89,000
43,600
0
0
46
14
0
014460043,60089,0000001584601,013636505974262784598
       Net Receivables 
137
977
1,767
1,289
2,753
3,617
2,483
8,345
5,734
3,146
4,112
3,367
5,951
6,840
31,699
7,914
24,482
59,147
18,844
18,84459,14724,4827,91431,6996,8405,9513,3674,1123,1465,7348,3452,4833,6172,7531,2891,767977137
       Other Current Assets 
0
0
0
0
0
0
0
87
135
3,157
4,129
4,806
9,498
7,956
33,881
23,773
25,479
64,404
22,665
22,66564,40425,47923,77333,8817,9569,4984,8064,1293,157135870000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
3,376
3,801
52,337
96,498
114,820
170,500
202,017
306,121
283,509
322,528
322,528283,509306,121202,017170,500114,82096,49852,3373,8013,376000000000
       Property Plant Equipment 
35
95
164
237
1,051
1,213
1,131
1,054
1,134
1,069
1,456
2,440
3,574
16,961
59,520
84,396
94,037
99,496
107,677
107,67799,49694,03784,39659,52016,9613,5742,4401,4561,0691,1341,0541,1311,2131,0512371649535
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
3,814
8,016
5,233
5,233
5,233
5,233
5,233
5,233
5,2335,2335,2335,2335,2335,2338,0163,81400000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
214
2,119
198
165
0
0
22,860
0
0
0022,860001651982,1192140000000000
       Intangible Assets 
650
538
354
735
568
486
416
1,826
1,960
1,887
1,725
41,649
78,234
79,130
80,385
81,907
87,490
89,005
104,954
104,95489,00587,49081,90780,38579,13078,23441,6491,7251,8871,9601,826416486568735354538650
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
61
463
3,871
90,131
44,738
2,644
3,436
62,116
20,796
41,208
41,20820,79662,1163,4362,64444,73890,1313,87146361000000000
> Total Liabilities 
591
1,665
1,911
2,087
3,836
4,894
6,167
10,391
9,577
7,643
9,416
55,495
78,193
79,681
157,830
204,791
234,345
364,248
388,078
388,078364,248234,345204,791157,83079,68178,19355,4959,4167,6439,57710,3916,1674,8943,8362,0871,9111,665591
   > Total Current Liabilities 
293
1,439
1,721
1,516
2,802
3,908
4,541
7,853
7,615
6,315
8,177
28,916
34,540
27,705
52,217
36,081
47,799
70,747
95,793
95,79370,74747,79936,08152,21727,70534,54028,9168,1776,3157,6157,8534,5413,9082,8021,5161,7211,439293
       Short-term Debt 
0
0
0
0
0
0
0
0
0
3,597
3,446
23,214
17,854
6,955
16,237
12,578
13,272
18,792
53,128
53,12818,79213,27212,57816,2376,95517,85423,2143,4463,597000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
4,685
105
904
6,955
16,237
10,443
6,526
11,477
46,567
46,56711,4776,52610,44316,2376,9559041054,6850000000000
       Accounts payable 
42
1,282
1,270
1,185
1,771
2,816
2,710
3,695
2,136
1,418
2,581
5,393
4,613
9,312
16,141
13,071
19,449
23,325
16,915
16,91523,32519,44913,07116,1419,3124,6135,3932,5811,4182,1363,6952,7102,8161,7711,1851,2701,28242
       Other Current Liabilities 
110
58
293
138
413
383
530
2,765
2,667
1,300
2,150
309
12,073
11,438
19,839
10,062
14,985
28,594
25,750
25,75028,59414,98510,06219,83911,43812,0733092,1501,3002,6672,76553038341313829358110
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
1,328
1,239
26,579
43,653
51,976
105,613
168,710
186,546
293,501
292,285
292,285293,501186,546168,710105,61351,97643,65326,5791,2391,328000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
29,183
39,987
48,736
67,370
64,784
0
0
0064,78467,37048,73639,98729,183000000000000
       Other Liabilities 
0
0
0
136
0
0
0
19
38
1
0
0
5,957
3,734
2,365
6,484
8,809
8,336
9,251
9,2518,3368,8096,4842,3653,7345,9570013819000136000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,575
3,105
7,441
12,036
19,917
19,91712,0367,4413,1051,57500000000000000
> Total Stockholder Equity
961
1,051
1,140
1,589
1,978
2,557
1,082
3,593
3,966
2,005
2,488
5,524
127,394
93,015
86,882
150,893
163,298
157,737
33,840
33,840157,737163,298150,89386,88293,015127,3945,5242,4882,0053,9663,5931,0822,5571,9781,5891,1401,051961
   Common Stock
1,919
3,136
3,153
3,376
3,380
3,380
3,480
2,480
2,480
2,480
5,041
3,107
22,613
22,613
25,036
26,925
28,018
31,271
32,250
32,25031,27128,01826,92525,03622,61322,6133,1075,0412,4802,4802,4803,4803,3803,3803,3763,1533,1361,919
   Retained Earnings Total Equity0000000000000000000
   Accumulated Other Comprehensive Income 0-7,451-4,925-5,617-3,265-1,604-1,232-1,036-700-545000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
122,830
122,830
148,279
221,587
259,529
0
0
00259,529221,587148,279122,830122,830000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
545
700
11,607
124,037
124,390
151,485
227,142
267,878
353,676
338,223
338,223353,676267,878227,142151,485124,390124,03711,607700545000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue22,668
Cost of Revenue-15,724
Gross Profit6,9446,944
 
Operating Income (+$)
Gross Profit6,944
Operating Expense-94,820
Operating Income-87,875-87,876
 
Operating Expense (+$)
Research Development85,243
Selling General Administrative12,515
Selling And Marketing Expenses1,871
Operating Expense94,82099,629
 
Net Interest Income (+$)
Interest Income0
Interest Expense-11,765
Net Interest Income-10,304-11,765
 
Pretax Income (+$)
Operating Income-87,875
Net Interest Income-10,304
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-123,769-51,981
EBIT - interestExpense = -123,770
-123,770
-105,110
Interest Expense11,765
Earnings Before Interest and Taxes (ebit)-112,005-112,004
Earnings Before Interest and Taxes (ebitda)-101,579
 
After tax Income (+$)
Income Before Tax-123,769
Tax Provision--6,895
Net Income From Continuing Ops-116,875-116,874
Net Income-116,875
Net Income Applicable To Common Shares-116,875
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses110,544
Total Other Income/Expenses Net-35,89410,304
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
NGU24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGU24-NYM.COMM.

NGU24-NYM.COMM Daily Candlestick Chart
NGM24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGM24-NYM.COMM.

NGM24-NYM.COMM Daily Candlestick Chart
NGQ24-NYM.COMM
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGQ24-NYM.COMM.

NGQ24-NYM.COMM Daily Candlestick Chart
ISKJ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ISKJ.MCX.

ISKJ.MCX Daily Candlestick Chart
CHKZ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CHKZ.MCX.

CHKZ.MCX Daily Candlestick Chart
VSYD.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VSYD.MCX.

VSYD.MCX Daily Candlestick Chart
VRSB.MCX
2 hours ago

I found you a Golden Cross on the daily chart of VRSB.MCX.

VRSB.MCX Daily Candlestick Chart
TBRU.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBRU.MCX.

TBRU.MCX Daily Candlestick Chart
SNGSP.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SNGSP.MCX.

SNGSP.MCX Daily Candlestick Chart
RBCM.MCX
2 hours ago

I found you a Golden Cross on the daily chart of RBCM.MCX.

RBCM.MCX Daily Candlestick Chart
OKEY.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of OKEY.MCX.

OKEY.MCX Daily Candlestick Chart
MTLR.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MTLR.MCX.

MTLR.MCX Daily Candlestick Chart
MRKZ.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MRKZ.MCX.

MRKZ.MCX Daily Candlestick Chart
KRKN.MCX
2 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of KRKN.MCX.

KRKN.MCX Daily Candlestick Chart
JNOS.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JNOS.MCX.

JNOS.MCX Daily Candlestick Chart
BLNG.MCX
2 hours ago

I found you a Golden Cross on the daily chart of BLNG.MCX.

BLNG.MCX Daily Candlestick Chart
ASSB.MCX
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ASSB.MCX.

ASSB.MCX Daily Candlestick Chart
CSYZ.MU
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CSYZ.MU.

CSYZ.MU Daily Candlestick Chart
MOH.MU
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MOH.MU.

MOH.MU Daily Candlestick Chart
TBK.V
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBK.V.

TBK.V Daily Candlestick Chart
UMDK.F
2 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of UMDK.F.

UMDK.F Daily Candlestick Chart
RY4C.BE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of RY4C.BE.

RY4C.BE Daily Candlestick Chart
PLY.BE
2 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PLY.BE.

PLY.BE Daily Candlestick Chart
PDL.LSE
2 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PDL.LSE.

PDL.LSE Daily Candlestick Chart
27F0.MU
2 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of 27F0.MU.

27F0.MU Daily Candlestick Chart